Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma

British Journal of Haematology

Volumn 159, Issue 3, 2012, Pages 329-339

  Minn, Ann Y ^a   Riedel, Elyn ^b   Halpern, Jerry ^a   Johnston, Laura J ^a   Horning, Sandra J ^c   Hoppe, Richard T ^a   Goodman, Karyn A ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c GENENTECH INC   (United States)

Author keywords

Bmt; High dose therapy; Hodgkins lymphoma; Hsc transplantation; Radiotherapy

Indexed keywords

ALTRETAMINE; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOSIMETRY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CHILD; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; RISK; SEER PROGRAM; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867458961     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12038     Document Type: Article

References (43)

1. Andre, M., Henry-Amar, M., Blaise, D., Colombat, P., Fleury, J., Milpied, N., Cahn, J.Y., Pico, J.L., Bastion, Y., Kuentz, M., Nedellec, G., Attal, M., Ferme, C. & Gisselbrecht, C. (1998) Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood, 92, 1933-1940.
2. Bhatia, S., Robison, L.L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F. & Meadows, A.T. (1996) Breast cancer and other second neoplasms after childhood Hodgkin's disease. New England Journal of Medicine, 334, 745-751.
3. Bhatia, S., Robison, L.L., Francisco, L., Carter, A., Liu, Y., Grant, M., Baker, K.S., Fung, H., Gurney, J.G., McGlave, P.B., Nademanee, A., Ramsay, N.K., Stein, A., Weisdorf, D.J. & Forman, S.J. (2005) Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood, 105, 4215-4222.
4. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478-1484.
5. Darrington, D.L., Vose, J.M., Anderson, J.R., Bierman, P.J., Bishop, M.R., Chan, W.C., Morris, M.E., Reed, E.C., Sanger, W.G., Tarantolo, S.R., Weisenburger, D.D., Kessinger, A. & Armitage, J.O. (1994) Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology, 12, 2527-2534.
6. Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A. & on behalf of the EORTC Quality of life Group (2001) EORTC QLQ-C30 scoring manual. Brussels, Belgium.
7. Ferme, C., Mounier, N., Divine, M., Brice, P., Stamatoullas, A., Reman, O., Voillat, L., Jaubert, J., Lederlin, P., Colin, P., Berger, F. & Salles, G. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of Clinical Oncology, 20, 467-475.
8. Fine, J.P. & Gray, R.J. (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of American Statistical Association, 94, 496-509.
9. Forrest, D.L., Hogge, D.E., Nevill, T.J., Nantel, S.H., Barnett, M.J., Shepherd, J.D., Sutherland, H.J., Toze, C.L., Smith, C.A., Lavoie, J.C., Song, K.W., Voss, N.J., Gascoyne, R.D. & Connors, J.M. (2005) High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. Journal of Clinical Oncology, 23, 7994-8002.
10. Goodman, K.A., Riedel, E., Serrano, V., Gulati, S., Moskowitz, C.H. & Yahalom, J. (2008) Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 5240-5247.
11. Gray, R.J. (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics, 16, 1141-1154.
12. Hancock, S.L., Tucker, M.A. & Hoppe, R.T. (1993a) Breast cancer after treatment of Hodgkin's disease. Journal of the National Cancer Institute, 85, 25-31.
13. Hancock, S.L., Tucker, M.A. & Hoppe, R.T. (1993b) Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA, 270, 1949-1955.
14. Harrison, C.N., Gregory, W., Hudson, G.V., Devereux, S., Goldstone, A.H., Hancock, B., Winfield, D., MacMillan, A.K., Hoskin, P., Newland, A.C., Milligan, D. & Linch, D.C. (1999) High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. British Journal of Cancer, 81, 476-483.
15. Henry-Amar, M. & Dietrich, P.Y. (1993) Acute leukemia after the treatment of Hodgkin's disease. Hematology/oncology Clinics of North America, 7, 369-387.
16. Hoppe, R.T., Advani, R.H., Bierman, P.J., Bloomfield, C.D., Buadi, F., Djulgegovic, B., Forero, A., Gordon, L.I., Hernandez-Ilizaliturri, F.J., Kaminski, M.S., Love, G., Maloney, D.G., Mauch, P.M., Moore, J.O., Schilder, R.J., Weiss, L., Winter, J.N., Yahalom, J. & Zelenetz, A.D. (2006) Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 4, 210-230.
17. Horning, S.J., Chao, N.J., Negrin, R.S., Hoppe, R.T., Long, G.D., Hu, W.W., Wong, R.M., Brown, B.W. & Blume, K.G. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood, 89, 801-813.
18. Hudson, M.M., Poquette, C.A., Lee, J., Greenwald, C.A., Shah, A., Luo, X., Thompson, E.I., Wilimas, J.A., Kun, L.E. & Crist, W.M. (1998) Increased mortality after successful treatment for Hodgkin's disease. Journal of Clinical Oncology, 16, 3592-3600.
19. Jantunen, E., Itala, M., Siitonen, T., Koivunen, E., Leppa, S., Juvonen, E., Kuittinen, O., Lehtinen, T., Koistinen, P., Nyman, H., Nousiainen, T., Volin, L. & Remes, K. (2006) Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1, 482 patients transplanted in 1990-2003. European Journal of Haematology, 77, 114-119.
20. Johnston, L.J. & Horning, S.J. (2000) Autologous hematopoietic cell transplantation in Hodgkin's disease. Biology of Blood and Marrow Transplantation, 6, 289-300.
21. Kaplan, E. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
22. Lavoie, J.C., Connors, J.M., Phillips, G.L., Reece, D.E., Barnett, M.J., Forrest, D.L., Gascoyne, R.D., Hogge, D.E., Nantel, S.H., Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J., Toze, C.L., Voss, N.J. & Nevill, T.J. (2005) High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 106, 1473-1478.
23. van Leeuwen, F.E., Klokman, W.J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A.W., van Kerkhoff, E.H., van Heerde, P. & Somers, R. (1994) Second cancer risk following Hodgkin's disease: a 20-year follow-up study. Journal of Clinical Oncology, 12, 312-325.
24. Lund, M.B., Kongerud, J., Nome, O., Abrahamsen, A.F., Bjortuft, O., Forfang, K. & Boe, J. (1995) Lung function impairment in long-term survivors of Hodgkin's disease. Annals of Oncology, 6, 495-501.
25. Mauch, P.M., Kalish, L.A., Marcus, K.C., Coleman, C.N., Shulman, L.N., Krill, E., Come, S., Silver, B., Canellos, G.P. & Tarbell, N.J. (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood, 87, 3625-3632.
26. Mink, S.A. & Armitage, J.O. (2001) High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous stem cell transplantation in Hodgkin's disease and non-Hodgkin's lymphoma. The Oncologist, 6, 247-256.
27. Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzalez, M., Zelenetz, A.D. & Yahalom, J. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal of Haematology, 124, 645-652.
28. Ng, A.K. & Mauch, P.M. (2006) The impact of treatment on the risk of second malignancy after Hodgkin's disease. Annals of Oncology, 17, 1727-1729.
29. Ng, A.K., Bernardo, M.P., Weller, E., Backstrand, K.H., Silver, B., Marcus, K.C., Tarbell, N.J., Friedberg, J., Canellos, G.P. & Mauch, P.M. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. Journal of Clinical Oncology, 20, 2101-2108.
30. Pai, V.B. & Nahata, M.C. (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety, 22, 263-302.
31. Pedersen-Bjergaard, J., Pedersen, M., Myhre, J. & Geisler, C. (1997) High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia, 11, 1654-1660.
32. Schwarz, R. & Hinz, A. (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. European Journal of Cancer, 37, 1345-1351.
33. Sirohi, B., Cunningham, D., Powles, R., Murphy, F., Arkenau, T., Norman, A., Oates, J., Wotherspoon, A. & Horwich, A. (2008) Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology, 19, 1312-1319.
34. Steinherz, L.J., Steinherz, P.G., Tan, C.T., Heller, G. & Murphy, M.L. (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 266, 1672-1677.
35. Steinherz, L.J., Steinherz, P.G. & Tan, C. (1995) Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Medical and Pediatric Oncology, 24, 352-361.
36. Swerdlow, A.J., Schoemaker, M.J., Allerton, R., Horwich, A., Barber, J.A., Cunningham, D., Lister, T.A., Rohatiner, A.Z., Vaughan Hudson, G., Williams, M.V. & Linch, D.C. (2001) Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. Journal of Clinical Oncology, 19, 1610-1618.
37. Swerdlow, A.J., Higgins, C.D., Smith, P., Cunningham, D., Hancock, B.W., Horwich, A., Hoskin, P.J., Lister, A., Radford, J.A., Rohatiner, A.Z. & Linch, D.C. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. Journal of the National Cancer Institute, 99, 206-214.
38. Tarbell, N.J., Gelber, R.D., Weinstein, H.J. & Mauch, P. (1993) Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet, 341, 1428-1432.
39. Travis, L.B., Gospodarowicz, M., Curtis, R.E., Clarke, E.A., Andersson, M., Glimelius, B., Joensuu, T., Lynch, C.F., van Leeuwen, F.E., Holowaty, E., Storm, H., Glimelius, I., Pukkala, E., Stovall, M., Fraumeni, Jr, J.F., Boice, Jr, J.D. & Gilbert, E. (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. Journal of the National Cancer Institute, 94, 182-192.
40. Travis, L.B., Hill, D.A., Dores, G.M., Gospodarowicz, M., van Leeuwen, F.E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C.F., Van't Veer, M.B., Glimelius, I., Storm, H., Pukkala, E., Stovall, M., Curtis, R., Boice, Jr, J.D. & Gilbert, E. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA, 290, 465-475.
41. Tucker, M.A., Coleman, C.N., Cox, R.S., Varghese, A. & Rosenberg, S.A. (1988) Risk of second cancers after treatment for Hodgkin's disease. New England Journal of Medicine, 318, 76-81.
42. Tucker, M.A., Jones, P.H., Boice, Jr, J.D., Robison, L.L., Stone, B.J., Stovall, M., Jenkin, R.D., Lubin, J.H., Baum, E.S., Siegel, S.E., Meadows, A.T., Hoover, R.N. & Fraumeni, Jr, J.F. (1991) Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Research, 51, 2885-2888.
43. Yuen, A.R., Rosenberg, S.A., Hoppe, R.T., Halpern, J.D. & Horning, S.J. (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood, 89, 814-822.